Simple Vaccination and Prevention Model of Respiratory Syncytial Virus

Nugraha, Edwin Setiawan; Nuraini, Nuning

doi:10.17654/ms102091865

Cited by 3 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most studies considered RSV vaccination in high-income countries: five in the USA [20][21][22][23][24], three in Spain [25][26][27], four in the Netherlands [28][29][30][31], two in England [32,33], and one each in Australia [34], and Turkey [35]. Four studies used data from Kenya [3,[36][37][38].…”

Section: Settings and Target Populationmentioning

confidence: 99%

“…Two studies explored RSV interventions in the countries supported by the Global Alliance for Vaccines and Immunisation (Gavi) [39,40]. Eleven studies evaluated both economic and epidemiological impacts [20, 23, 25-30, 32, 35, 40], and 11 studies provided an evaluation of only epidemiological effects [3,21,22,24,31,33,34,[36][37][38][39]. Nineteen studies evaluated interventions that target the reduction of RSV infections in infants and children aged < 5 years, and three studies examined vaccination impact on morbidity and mortality in the elderly [20,24,29].…”

Section: Settings and Target Populationmentioning

confidence: 99%

“…In the dynamic models, the natural history of RSV infection was approximated by the susceptible-infected-recovered-susceptible (SIRS) model, including the protection of newborns by maternal antibodies as described by Weber et al [41]. Extensions of the model included a latent period (exposed compartment) of infection [21,34], subsequent (milder) illness with reduced duration of infectiousness [24,36], reduction of susceptibility [3,36,37] and infectivity in previously infected individuals [36,37] or children aged > 10 years [34] and adults [24]. Pan-Ngum et al [37] and Kinyanjui et al [33] addressed in detail the uncertainty around the acquisition and duration of immunity after primary RSV infection and explored the impact of lifelong and short-term partial immunity after a primary RSV infection.…”

Section: The Natural History Of Rsvmentioning

confidence: 99%

“…Most studies used either infections [3,21,[24][25][26][27]31] or hospitalisations [20,23,28,33,34,36,[38][39][40] as epidemiological ends. Eight studies distinguished between an asymptomatic and symptomatic course of infection and modelled different severity of RSV disease within either a dynamic [33,37] or static [22,29,30,32,35,39,40] framework.…”

Section: The Natural History Of Rsvmentioning

confidence: 99%

“…Eleven studies graphically illustrated monthly or weekly series of RSV cases (hospitalisations) Optimal target product profile over the studied years in the modelled population. The approaches to estimating incidence among children were based on linkage of laboratory data to available administrative data [31,32,34], data from the hospital reporting system [3,27,33,[36][37][38], and observational studies [20,21,23,[28][29][30]35]. Two studies that evaluated the intervention in Gavi-eligible countries obtained the data from a recent review [5], estimated the total burden of the disease for each of the countries, and used statistical modelling to address the lack of granularity in the data [39,40].…”

Section: Epidemiological Estimatesmentioning

confidence: 99%

See 4 more Smart Citations

Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data

et al. 2021

View full text Add to dashboard Cite

Background Several vaccine and antibody candidates are currently in development for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus (RSV). Methods We searched MEDLINE, Embase, and SCOPUS and included model-based evaluations of RSV vaccinations. Two reviewers performed the selection, data extraction, and quality evaluation with EVIDEM. Cost-effectiveness (CE) estimates were converted to $US purchasing power parity (PPP), year 2018 values. Potential economic and epidemiological outcomes were summarised for maternal, infant, children, and elderly vaccinations. The PROSPERO identifier is CRD42019122570. Results In total, 22 model-based studies were reviewed. On average, a potential 27% reduction in RSV hospitalisations in infants was projected for maternal vaccination and 50% for direct infant immunisation. The CE of maternal vaccination was $US1766-5857 PPP 2018/disability-adjusted life-years (DALYs) for Global Alliance for Vaccines and Immunisation (Gavi)-eligible countries. For England, the maximum cost-effective price of maternal vaccination was estimated at $US81.5 PPP 2018. Infant vaccination was associated with higher CE ratios in low-and high-income settings. Vaccination of neonates born before the RSV season was the most cost effective in high-income settings. Higher values for vaccine effectiveness, duration of protection, and vaccine uptake increased the benefits. Due to indirect effects, the vaccination of school-age children and a cocooning strategy were effective alternatives to protect infants, and the vaccination of children aged < 5 years had a beneficial impact on the elderly. Conclusion RSV vaccines with anticipated characteristics may reduce a sizeable proportion of the RSV burden. The results are subject to uncertainty because of the limited epidemiological and clinical data. Data on RSV incidence and hospitalisation risk for granular age strata should be prioritised to facilitate the evaluation of RSV interventions and decision making.

show abstract

Section: Settings and Target Populationmentioning

confidence: 99%

Section: Settings and Target Populationmentioning

confidence: 99%

Section: The Natural History Of Rsvmentioning

confidence: 99%

Section: The Natural History Of Rsvmentioning

confidence: 99%

Section: Epidemiological Estimatesmentioning

confidence: 99%

See 3 more Smart Citations

Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data

et al. 2021

View full text Add to dashboard Cite

show abstract

Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review

Lang

2022

J. Math. Biol.

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection worldwide, resulting in approximately sixty thousand annual hospitalizations of< 5-year-olds in the United States alone and three million annual hospitalizations globally. The development of over 40 vaccines and immunoprophylactic interventions targeting RSV has the potential to significantly reduce the disease burden from RSV infection in the near future. In the context of RSV, a highly contagious pathogen, dynamic transmission models (DTMs) are valuable tools in the evaluation and comparison of the effectiveness of different interventions. This review, the first of its kind for RSV DTMs, provides a valuable foundation for future modelling efforts and highlights important gaps in our understanding of RSV epidemics. Specifically, we have searched the literature using Web of Science, Scopus, Embase, and PubMed to identify all published manuscripts reporting the development of DTMs focused on the population transmission of RSV. We reviewed the resulting studies and summarized the structure, parameterization, and results of the models developed therein. We anticipate that future RSV DTMs, combined with cost-effectiveness evaluations, will play a significant role in shaping decision making in the development and implementation of intervention programs.

show abstract

Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: A literature review

Lang¹

2021

Preprint

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection worldwide, resulting in approximately sixty thousand annual hospitalizations of < 5-year-olds in the United States alone and three million annual hospitalizations globally. The development of over 40 vaccines and immunoprophylactic interventions targeting RSV has the potential to significantly reduce the disease burden from RSV infection in the near future. In the context of RSV, a highly contagious pathogen, dynamic transmission models (DTMs) are valuable tools in the evaluation and comparison of the effectiveness of different interventions. This review, the first of its kind for RSV DTMs, provides a valuable foundation for future modelling efforts and highlights important gaps in our understanding of RSV epidemics. Specifically, we have searched the literature using Web of Science, Scopus, Embase, and PubMed to identify all published manuscripts reporting the development of DTMs focused on the population transmission of RSV. We reviewed the resulting studies and summarized the structure, parameterization, and results of the models developed therein. We anticipate that future RSV DTMs, combined with cost-effectiveness evaluations, will play a significant role in shaping decision making in the development and implementation of intervention programs.

show abstract

Simple Vaccination and Prevention Model of Respiratory Syncytial Virus

Cited by 3 publications

References 0 publications

Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data

Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data

Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: a literature review

Use of mathematical modelling to assess respiratory syncytial virus epidemiology and interventions: A literature review

Contact Info

Product

Resources

About